JPMorgan plans to hire a dozen research analysts for China brokerage: sources


HONG KONG/WASHINGTON (Reuters) – JPMorgan Chase & Co (JPM.N) plans to hire at least 12 equity research analysts in China this year, two people with knowledge of the matter said, in its first major mainland hiring push as it takes advantage of eased ownership rules for financial firms.

FILE PHOTO – A view of the exterior of the JP Morgan Chase & Co. Corporate headquarters in the Manhattan borough of New York City, May 20, 2015. REUTERS/Mike Segar

With the headcount expansion for its new brokerage business, the bank’s research arm aims to more than double the number

Read More

These companies fighting the coronavirus will pay off the most for investors, analysts say


President Donald Trump speaks in the Rose Garden after introducing a new point-of-care COVID-19 test kit developed by Abbott Labs at the White House on March 30, 2020 in Washington, DC.

Win McNamee | Getty Images

A handful of drug companies are on the front lines of fighting the deadly coronavirus and Wall Street is watching closely for which stocks will bank the breakthroughs.

CNBC’s Covid-19 Testing & Treatments Index is equal-weighed and currently comprised of 29 companies that are working on testing and treating the novel coronavirus. Its components are a mixture of pharmaceutical and biotechnology companies ranging from 

Read More

Remote work revenue could help Microsoft offset coronavirus impacts, analysts say


FILE PHOTO: The Microsoft logo is shown on the Microsoft Theatre at the E3 2017 Electronic Entertainment Expo in Los Angeles, California, U.S. June 13, 2017. REUTERS/ Mike Blake

(Reuters) – When Microsoft Corp reports earnings on Wednesday, analysts expect some areas of its business to take a hit from the novel coronavirus pandemic, with lower-than-expected sales in areas like advertising on its LinkedIn social network.

But analysts also expect a surge in the use of Microsoft’s cloud computing services and collaboration tools such as the Teams app “as more companies are effectively forced into the cloud” by stay-home orders,

Read More

Investors should be cautious, analysts says


A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

David Paul Morris | Bloomberg | Getty Images

A new report from STAT News on Gilead’s experimental drug Remdesivir serves as an encouraging update on the drug’s potential to fight Covid-19, however analysts argue it’s largely anecdotal and should be interpreted with caution. 

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial

Read More